New Delhi: A groundbreaking study on Tuesday unveiled a novel nasal and needle-free COVID-19 vaccine, licenced to Hyderabad-based Indian Immunologicals, that holds the potential to revolutionise the global battle against the infectious disease.
The study led by a team from Griffith University in Australia investigated the effectiveness of administering a Covid vaccination — CDO-7N-1 — through the nasal passages.
“This is a live attenuated intranasal vaccine, called CDO-7N-1, designed to be administered intranasally, thereby inducing potential mucosal immunity as well as systemic immunity with just a single dose,” said Professor Suresh Mahalingam of Griffith’s Institute for Biomedicine and Glycomics.
The research, published in the journal Nature Communications, showed that the vaccine induces strong memory responses in the nasal mucosa, offering long-term protection for up to a year or more.
“It’s been designed to be administered as a single dose, ideally as a booster vaccine, as a safe alternative to needles with no adverse reactions in the short or long term,” Mahalingam reassured.
Compared to alternative vaccination strategies, live-attenuated vaccines provide several important advantages.
Their effects on humoral and cellular immunity are strong and persistent but frequently require a dose.
Unlike many other vaccine platforms that use a single antigen, live-attenuated vaccines like CDO-7N-1 include the complete virus, resulting in broad immunity, providing a strong shield against the virus.
Dr Xiang Liu, the study’s lead author, noted that CDO-7N-1 “provides cross-protection against all variants of concern” and has a neutralising capacity against SARS-CoV-1, the respiratory illness responsible for the 2002–2004 SARS outbreak.
“The vaccine offers potent protection against transmission, prevents reinfection and the spread of the virus while reducing the generation of new variants,” Liu said.
“Unlike the mRNA vaccine, which targets only the spike protein, CDO-7N-1 induces immunity to all major SARS-CoV-2 proteins and is highly effective against all major variants to date. Importantly, the vaccine remains stable at 4 degrees Celsius for seven months, making it ideal for low- and middle-income countries,” Liu added.
The vaccine has been licenced by Indian Immunologicals — a significant vaccine producer for human and animal use.
Dr. K. Anand Kumar, Managing Director of Indian Immunologicals, said the company has “completed all the necessary studies of the vaccine” and now plans to launch “clinical trials.”
For more updates Subscribe to Media Eye News
–IANS
